188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer

EANM Innovation · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles